Abstract
Negative and cognitive symptoms of schizophrenia remain difficult to treat. Many add-on medications to alleviate these symptoms have been proposed and investigated. In this inventory the various treatment strategies published since 1990 are being reviewed and categorised according to the pharmacological mechanism putatively involved. Notwithstanding the problems one experiences when comparing the applied measures for negative and cognitive symptoms, three clear recommendations for future research can be made viz. modulation of glutamatergic systems, blockade of serotonin 5-HT2 receptors and modulation of histaminergic systems. Strategies aimed at nAChR subtypes may also hold some promise.
Keywords: Schizophrenia, negative symptoms, cognitive dysfunction, add-on medication
Central Nervous System Agents in Medicinal Chemistry
Title: Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Volume: 8 Issue: 1
Author(s): Gerben Duisterwinkel, F. J. Bosker, A. N. Scholte-Stalenhoef, M. Vervoort and H. Knegtering
Affiliation:
Keywords: Schizophrenia, negative symptoms, cognitive dysfunction, add-on medication
Abstract: Negative and cognitive symptoms of schizophrenia remain difficult to treat. Many add-on medications to alleviate these symptoms have been proposed and investigated. In this inventory the various treatment strategies published since 1990 are being reviewed and categorised according to the pharmacological mechanism putatively involved. Notwithstanding the problems one experiences when comparing the applied measures for negative and cognitive symptoms, three clear recommendations for future research can be made viz. modulation of glutamatergic systems, blockade of serotonin 5-HT2 receptors and modulation of histaminergic systems. Strategies aimed at nAChR subtypes may also hold some promise.
Export Options
About this article
Cite this article as:
Duisterwinkel Gerben, Bosker J. F., Scholte-Stalenhoef N. A., Vervoort M. and Knegtering H., Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/187152408783790631
DOI https://dx.doi.org/10.2174/187152408783790631 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox
Current Vascular Pharmacology Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Current Gene Therapy Cellular Mechanisms in Perinatal Hypoxic-Ischemic Brain Injury
Current Pediatric Reviews The Validity of Chemical Analytical Methods by the Example of the Heparin Product Recall
Current Pharmaceutical Analysis Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pain-Relief Medication and Risk of Fractures
Current Drug Safety Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Developments in the Therapeutic Potential of S-Nitrosoglutathione, an Endogenous NO-Donor Molecule
Current Pharmaceutical Biotechnology Possible Human Endogenous Cryogens
Current Protein & Peptide Science Effects of Remifentanil on the Cardiac Conduction System. Our Experience in the Study of Remifentanil Electrophysiological Properties
Current Pharmaceutical Design Central Nervous System Agents Used as Trypanosoma cruzi Infection Chemotherapy: Phenothiazines and Related Compounds
Current Medicinal Chemistry - Anti-Infective Agents Orthostatic Hypotension: Evaluation and Treatment
Cardiovascular & Hematological Disorders-Drug Targets Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies
Current Drug Targets Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews